Krka dd Novo mesto Reports Record Revenues and Strong Profit Growth
Krka dd Novo mesto, a leading pharmaceutical company listed on the Warsaw Stock Exchange, announced that its 2025 group revenues exceeded two billion euros for the first time. The company reported a 7 % increase in sales compared with the previous year, reaching €2.04 billion.
The growth was driven primarily by stronger performance in all regions outside the core European market. While sales in overseas markets fell by 6 % to €76 million, the company achieved higher volumes in its remaining operating regions, compensating for the decline and delivering the overall revenue milestone.
In addition to the revenue achievement, Krka disclosed that its net profit surpassed €400 million. This profit figure reflects an improvement in profitability, reinforcing the company’s financial strength.
Krka’s market capitalization stands at 7.38 billion PLN, with a price‑to‑earnings ratio of 17.46. The latest closing price on 27 January 2026 was 960 PLN, within a 52‑week range of 640–966 PLN.
The company’s management has outlined a plan to achieve a 5.6 % annual growth in earnings over the next five years, indicating a continued focus on expanding profitability in both existing and new markets.
